| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| Other Sizes |
| Targets |
Dehydrocavidine targets multiple cellular pathways involved in apoptosis and cell proliferation. It induces apoptosis mediated by regulating Bax/Bcl-2, activating caspases, and cleaving PARP (poly ADP-ribose polymerase). It modulates pathways involved in inflammation, oxidative stress, and cell signaling. Dehydrocavidine also has potential to influence drug metabolism through interactions with metabolic enzymes. Its hepatoprotective and antiviral activities suggest additional targets related to hepatitis virus replication and hepatocyte regeneration. The compound's antinociceptive effects indicate interactions with pain signaling pathways.
|
|---|---|
| ln Vitro |
In vitro, Dehydrocavidine exhibits antitumor activity by inhibiting MCF-7 cell proliferation through induction of apoptosis mediated by regulating Bax/Bcl-2, activating caspases, and cleaving PARP. It displays antinociceptive, hepatoprotective, and spasmolytic activities in various assays. It kills hepatitis viruses and promotes regeneration of hepatocytes. The complexation behavior of dehydrocavidine with cucurbit[7]uril (CB7) has been studied in phosphate buffer saline (pH 7.2), showing significant fluorescence enhancement upon complexation. Although structurally similar to other alkaloids, the complexation stability constant of dehydrocavidine with CB7 is 5.4 times lower than that of palmatine.
|
| ln Vivo |
In vivo activity data for Dehydrocavidine is limited in publicly available literature. As an active ingredient of Corydalis saxicola used in traditional medicine, it is believed to exhibit hepatoprotective, antinociceptive, and spasmolytic effects in vivo. It kills hepatitis viruses and promotes hepatocyte regeneration. However, specific in vivo efficacy studies, including detailed pharmacokinetic and pharmacodynamic parameters, have not been extensively reported. Its potential to influence drug metabolism suggests that in vivo herb-drug interaction studies would be important for understanding its clinical relevance.
|
| Enzyme Assay |
For in vitro cell-free assays, the apoptotic activity of dehydrocavidine can be studied by measuring its effects on Bax/Bcl-2 ratio, caspase activation, and PARP cleavage using purified proteins or cell lysates. Caspase activity assays using fluorogenic substrates (e.g., DEVD-AFC for caspase-3) can quantify enzyme activation. PARP cleavage can be detected by Western blot using specific antibodies. The complexation behavior with cucurbit[7]uril (CB7) can be studied by fluorescence spectroscopy in phosphate buffer saline (pH 7.2), monitoring fluorescence enhancement upon complex formation.
|
| Cell Assay |
For in vitro cellular assays, the antitumor activity of dehydrocavidine is assessed in MCF-7 breast cancer cells. Cells are seeded in multi-well plates and treated with various concentrations of dehydrocavidine for a defined period. Cell viability is measured using MTT or SRB assays. Apoptosis is assessed by flow cytometry (Annexin V/PI staining), caspase activity assays, and Western blot analysis of Bax/Bcl-2 expression and PARP cleavage. The effect on cell cycle progression can also be evaluated. For hepatoprotective studies, liver cell lines can be used to assess protection against toxin-induced damage.
|
| Animal Protocol |
For in vivo studies, dehydrocavidine could be administered orally or intraperitoneally in rodent models of liver injury, pain, or cancer. In hepatoprotective studies, endpoints include serum liver enzyme levels (ALT, AST), histopathological examination of liver tissue, and assessment of hepatocyte regeneration. In antinociceptive studies, pain responses can be measured using standard tests such as the hot plate test or acetic acid-induced writhing test. Its potential to influence drug metabolism could be studied by measuring the pharmacokinetics of co-administered drugs.
|
| ADME/Pharmacokinetics |
Dehydrocavidine (CAS 83218-34-2) has a molecular formula of C21H18NO4 and a molecular weight of 348.37 g/mol. It is also known as Dehydrocorydaline. The compound is typically supplied as a powder. It is soluble in DMSO and other organic solvents. Storage: powder at -20°C for 3 years; in solvent at -80°C for 1 year. Purity is typically >98% for research use. The compound should be protected from light and moisture. Density data is not available.
|
| Toxicity/Toxicokinetics |
No detailed toxicity data is publicly available for dehydrocavidine. As an alkaloid from Corydalis saxicola used in traditional medicine, it is generally considered to have a manageable safety profile, but standard toxicological studies would be required for drug development. In vitro cytotoxicity assays in various cell lines are typically performed alongside efficacy studies to confirm that observed effects are not due to a general reduction in cell viability. Its potential to influence drug metabolism suggests that herb-drug interaction risks should be evaluated.
|
| Additional Infomation |
Benzo(a)-1,3-benzodioxane(4,5-g)quinolazine, 8,9-dimethoxy-6-methyl- has been reported in corydalis, berberis and other organisms for which data are available.
Dehydrocavidine is a research-grade compound and is not approved for therapeutic use. It serves primarily as a pharmacological tool for studying apoptosis, cancer cell biology, and hepatoprotection. Its mechanism of action involves the induction of apoptosis through regulation of Bax/Bcl-2, activation of caspases, and cleavage of PARP. It displays antinociceptive, hepatoprotective, and spasmolytic activities. As a main active ingredient of Corydalis saxicola Bunting (Yanhuanglian), it is used in traditional Chinese medicine. No clinical trials have been reported. Its potential to influence drug metabolism highlights the need for further investigation. |
| Molecular Formula |
C21H18NO4
|
|---|---|
| Molecular Weight |
348.3719
|
| Exact Mass |
351.147
|
| CAS # |
83218-34-2
|
| PubChem CID |
158329
|
| Appearance |
Typically exists as solid at room temperature
|
| Density |
1.3±0.1 g/cm3
|
| Boiling Point |
506.0±50.0 °C at 760 mmHg
|
| Flash Point |
149.9±27.3 °C
|
| Vapour Pressure |
0.0±1.3 mmHg at 25°C
|
| Index of Refraction |
1.663
|
| LogP |
5.01
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
26
|
| Complexity |
516
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O(C)C1C(OC)=CC2C(=CC=[N+]3C=2C(C)=C2C(C4=C(C=C2)OCO4)=C3)C=1
|
| InChi Key |
TWSZDJCOYVYRGM-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C21H18NO4/c1-12-14-4-5-17-21(26-11-25-17)16(14)10-22-7-6-13-8-18(23-2)19(24-3)9-15(13)20(12)22/h4-10H,11H2,1-3H3/q+1
|
| Chemical Name |
16,17-dimethoxy-12-methyl-5,7-dioxa-1-azoniapentacyclo[11.8.0.03,11.04,8.014,19]henicosa-1(13),2,4(8),9,11,14,16,18,20-nonaene
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.8705 mL | 14.3526 mL | 28.7051 mL | |
| 5 mM | 0.5741 mL | 2.8705 mL | 5.7410 mL | |
| 10 mM | 0.2871 mL | 1.4353 mL | 2.8705 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
